These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29655290)

  • 21. Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study.
    Chen G; Zhang D; Du A; Zhang Y; Zhang Y; Zhang L; Zang S; Liu X; Wang Z; Zhen H; Liu Y; Yang S; Wang J
    Pharmacotherapy; 2020 Jul; 40(7):623-631. PubMed ID: 32498113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
    Riggs MM; Seman LJ; Staab A; MacGregor TR; Gillespie W; Gastonguay MR; Woerle HJ; Macha S
    Br J Clin Pharmacol; 2014 Dec; 78(6):1407-18. PubMed ID: 24964723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
    Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
    Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X; Hu J
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
    Toyoshima J; Saito M; Kaibara A; Isaka H; Sakatani T
    Clin Ther; 2020 Sep; 42(9):1787-1798.e3. PubMed ID: 32839028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
    Glund S; Mattheus M; Runge F; Rose P; Friedrich C
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):355-367. PubMed ID: 28290274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
    Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
    Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Devi R; Mali G; Chakraborty I; Unnikrishnan MK; Abdulsalim S
    Postgrad Med; 2017 Apr; 129(3):382-392. PubMed ID: 27841714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
    Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
    Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt-Jacobsen NH; Gæde P; Rossing P; Faber J; Inzucchi SE; Gustafsson F; Kistorp C
    J Am Heart Assoc; 2021 Aug; 10(15):e020418. PubMed ID: 34278803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
    Refardt J; Imber C; Sailer CO; Jeanloz N; Potasso L; Kutz A; Widmer A; Urwyler SA; Ebrahimi F; Vogt DR; Winzeler B; Christ-Crain M
    J Am Soc Nephrol; 2020 Mar; 31(3):615-624. PubMed ID: 32019783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
    Macha S; Jungnik A; Hohl K; Hobson D; Salsali A; Woerle HJ
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):873-9. PubMed ID: 24152604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC
    Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.